In October 2019, Numab and Eisai announced a research and option agreement to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform. Under the terms of the agreement, Eisai has the option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules that emerge from the joint research collaboration. In exchange, Numab received an upfront payment in addition to research funding and is eligible to receive success fees, milestone payments, and tiered royalties on product sales.

For more information about Eisai, please visit: www.eisai.com

In May 2019, Numab entered into an exclusive regional licensing agreement for the development and commercialization of its most advanced proprietary asset NM21 with CStone Pharmaceuticals. Pursuant to the terms of the licensing agreement, CStone funds the research and development of NM21, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and serum albumin, up to completion of a first Phase 1b clinical trial. In exchange, CStone obtains exclusive rights to develop and commercialize NM21 in Greater China, including Mainland China, Hong Kong, Macau, and Taiwan, as well as South Korea and Singapore. Numab retains all NM21 rights for the rest of the world. Upon completion of CStone’s funding period, no further financial obligations will be owed by either party.

For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com

In March 2022, Numab announced a development and license agreement with Ono Pharmaceutical granting Ono exclusive rights to develop and commercialize a multispecific antibody candidate in immuno-oncology resulting from Numab’s research program NM23. NM23 was initiated under a research and option agreement concluded between Ono and Numab in 2017. In consideration for the discovery work and the license, Numab is eligible for up to CHF 258 million in research funding, upfront and milestone payments plus tiered single to double digit royalties on future sales.

In March 2020, Numab and Ono expanded their collaboration with a second multi-specific antibody drug program (ND039) for the treatment of various cancers. The financial terms involved in this second program largely match those of the initial collaboration, essentially doubling the potential commercial value of the relationship for Numab.

For more information about Ono Pharmaceutical, please visit www.ono.co.jp

In January 2021, Numab announced a global co-development and regional license agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory , which blocks three key pathways in the pathophysiology of atopic dermatitis. Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

The alliance builds on a collaboration and option agreement established in 2017.

For more information about Kaken Pharmaceutical, please visit www.kaken.co.jp

In June 2015, Numab and Tillotts Pharma announced an exclusive global license agreement to develop and commercialize antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). In 2023 Tillotts has spun this program into newly formed Mage Biologics that continues to clinically develop an orally administered anti-TNF antibody identified by Numab as part of the NM09 program. Numab is eligible to milestone payments and royalties on net sales.

For more information about Tillots Pharma, please visit www.tillotts.com.